Literature DB >> 11760795

Diffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors.

E Erdem1, R A Zimmerman, J C Haselgrove, L T Bilaniuk, J V Hunter.   

Abstract

The aim of our study was to determine whether fluid-attenuated inversion recovery (FLAIR) imaging and diffusion-weighted imaging (DWI) would be helpful in characterizing primitive neuroectodermal tumors (PNET) from other pediatric brain tumors. We expected that the compact cellular nature and the relatively small extracellular space of this tumor would affect the signal intensity on both pulse sequences relative to the more sparsely cellular glial tumors that have larger extracellular spaces. Eighteen pediatric patients with PNET were examined on a 1.5 T MRI with routine imaging plus FLAIR and compared with 28 patients with nonPNET. DWI was also performed in 7 PNET and 18 non-PNET. Seventyeight percent of PNET were isointense to gray matter on FLAIR while 82% of non-PNET were hyperintense and only one was isointense (3%). Diffusion was abnormally restricted in all 7 PNET examined (100%) but was restricted in non-PNET in only 1 out of 18 (6%) patients who had DWI. The differences in the histologic architecture between PNET and non-PNET are reflected in both FLAIR imaging and in DWI.

Entities:  

Mesh:

Year:  2001        PMID: 11760795     DOI: 10.1007/s002340100603

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  17 in total

1.  Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.

Authors:  Xianyuan Song; R Andrew Allen; S Terence Dunn; Kar-Ming Fung; Peter Farmer; Shital Gandhi; Tulika Ranjan; Alexis Demopoulos; Marc Symons; Michael Schulder; Jian Yi Li
Journal:  Int J Clin Exp Pathol       Date:  2011-09-17

2.  Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors.

Authors:  Meng Law; Khuram Kazmi; Stephan Wetzel; Edwin Wang; Codrin Iacob; David Zagzag; John G Golfinos; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

Review 3.  Neuroradiology of childhood brain tumors: new challenges.

Authors:  Louis-Gilbert Vézina
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 4.  Diffusion tensor MR imaging and fiber tractography: theoretic underpinnings.

Authors:  P Mukherjee; J I Berman; S W Chung; C P Hess; R G Henry
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-13       Impact factor: 3.825

5.  Freiburg Neuropathology Case Conference : Posterior Fossa Mass in an Infant.

Authors:  C A Taschner; D Erny; M J Shah; H Urbach; U Feige; M Prinz
Journal:  Clin Neuroradiol       Date:  2019-03       Impact factor: 3.649

6.  Primary intracranial atypical teratoid/rhabdoid tumors of infancy and childhood: MRI features and patient outcomes.

Authors:  S P Meyers; Z P Khademian; J A Biegel; S H Chuang; D N Korones; R A Zimmerman
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

Review 7.  Imaging of central nervous system tumors in children: advances and limitations.

Authors:  Louis-Gilbert Vézina
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 8.  Aggressive infantile embryonal tumors.

Authors:  Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

9.  Diffusion-weighted imaging to assess treatment response in a child with trilateral retinoblastoma.

Authors:  Gregory A Bonci; Marc K Rosenblum; Stephen W Gilheeney; Ira J Dunkel; Andrei I Holodny
Journal:  Pediatr Radiol       Date:  2013-03-12

Review 10.  The evolving role of neurological imaging in neuro-oncology.

Authors:  E J Fontana; T Benzinger; C Cobbs; J Henson; S J Fouke
Journal:  J Neurooncol       Date:  2014-08-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.